A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
Public ClinicalTrials.gov record NCT04153929. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Parallel Group, Dose-finding Study of Subcutaneously Administered BI 456906 for 16 Weeks, Compared With Placebo and Open-label Semaglutide in Patients With Type 2 Diabetes Mellitus.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is open to adults with type 2 diabetes who take metformin but still have too high blood sugar. The purpose of the study is to find the best dose of BI 456906 that reduces blood sugar. The study also looks at whether BI 456906 helps the participants lose weight. Participants are in the study for about 23 weeks. During this time, most participants visit the study site about 13 times. Some participants visit the study site about 20 times. At the start of the study, the participants are put into 7 groups. The participants in groups 1 to 6 get injections under the skin once or twice every week. Some participants get different doses of BI 456906 and other participants get placebo. Placebo injections look like the BI 456906 injections, but contain no medicine. Participants in group 7 get semaglutide injections every week. Semaglutide is another medicine for adults with type 2 diabetes. During the study, the doctors regularly take blood samples from the participants and measure their body weight. The changes in blood sugar levels and body weight are compared between the groups. The doctors also check the general health of the participants.
Study identification
- NCT ID
- NCT04153929
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 413 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 29, 2020
- Primary completion
- Oct 7, 2021
- Completion
- Nov 3, 2021
- Last update posted
- Nov 28, 2022
2020 – 2021
United States locations
- U.S. sites
- 31
- U.S. states
- 15
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Research Institute | Huntington Park | California | 90255 | — |
| National Research Institute | Los Angeles | California | 90057 | — |
| Valley Clinical Trials, Inc. | Northridge | California | 91325 | — |
| Indago Research and Health Center | Hialeah | Florida | 33012 | — |
| Meridien Research | Lakeland | Florida | 33803 | — |
| San Marcus Research Clinic, Inc. | Miami | Florida | 33014 | — |
| Renstar Medical Research | Ocala | Florida | 34470 | — |
| Sensible Healthcare, LLC | Ocoee | Florida | 34761 | — |
| Meridien Research | St. Petersburg | Florida | 33709 | — |
| In-Quest Medical Research, LLC | Suwanee | Georgia | 30024 | — |
| Solaris Clinical Research | Meridian | Idaho | 83646 | — |
| DuPage Medical Group, Ltd | Lombard | Illinois | 60148 | — |
| Iowa Diabetes and Endocrinology Research Center | West Des Moines | Iowa | 50265 | — |
| ActivMed Practices & Research | Methuen | Massachusetts | 01844 | — |
| StudyMetrix Research, LLC | City of Saint Peters | Missouri | 63303 | — |
| Mercury Street Medical | Butte | Montana | 59701 | — |
| Palm Research Center | Las Vegas | Nevada | 89148 | — |
| The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| PMG Research of Hickory, LLC | Hickory | North Carolina | 28602 | — |
| Lucas Research, Inc. | Morehead City | North Carolina | 28557 | — |
| PMG Research of Raleigh, LLC | Raleigh | North Carolina | 27609 | — |
| PMG Research of Piedmont Healthcare | Statesville | North Carolina | 28625 | — |
| PMG Research of Wilmington, LLC | Wilmington | North Carolina | 28401 | — |
| PMG Research of Winston-Salem | Winston-Salem | North Carolina | 27103 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| Lillestol Research, LLC | Fargo | North Dakota | 58104 | — |
| Heritage Valley Medical Group | Beaver | Pennsylvania | 15009 | — |
| PMG Research of Knoxville | Knoxville | Tennessee | 37938 | — |
| Dallas Diabetes and Endocrine Center | Dallas | Texas | 75230 | — |
| Clinical Trials of Texas, LLC | San Antonio | Texas | 78229 | — |
| Javara Research | Sugar Land | Texas | 77478 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04153929, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 28, 2022 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04153929 live on ClinicalTrials.gov.